Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Caterina Soldà"'
Autor:
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Publikováno v:
Liver Cancer (2024)
Introduction The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post-hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD
Externí odkaz:
https://doaj.org/article/3da67a4e9b81471598019e46c12fc527
Autor:
Ottavia De Simoni, Luca Dal Santo, Marco Scarpa, Giada Munari, Ylenia Camilla Spolverato, Antonio Scapinello, Sara Lonardi, Caterina Soldà, Francesca Bergamo, Alberto Fantin, Romeo Bardini, Pierluigi Pilati, Matteo Fassan, Mario Gruppo
Publikováno v:
Current Oncology, Vol 30, Iss 6, Pp 5515-5528 (2023)
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly immunosuppressive tumor microenvironment (TME). The aim of this study is to determine the potential significant TME immune markers of long-term survival. Methods: We ret
Externí odkaz:
https://doaj.org/article/fa7eb0760d55495ea25d57cf95f1d5d9
Autor:
Antonella Galiano, Alessandra Feltrin, Ardi Pambuku, Leda Lo Mauro, Chiara De Toni, Sabina Murgioni, Caterina Soldà, Marco Maruzzo, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Background Veneto Institute of Oncology has activated a simultaneous care outpatient clinic (SCOC) in which cancer patients with advanced‐stage cancer are evaluated by oncologist and palliative care specialists. This cross‐sectional stud
Externí odkaz:
https://doaj.org/article/d1d125f1a4c5498d8c05e577abb3f4a2
Autor:
Margherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, Lorenza Rimassa, Ester Oneda, Caterina Soldà, Pasqua Cito, Guglielmo Nasti, Daniele Lavacchi, Valentina Zanuso, Mario Domenico Rizzato, Alberto Zaniboni, Alessandro Ottaiano, Mara Persano, Noemi Cornara, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The results of the phase III ClarIDHy trial led to the FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations. We
Externí odkaz:
https://doaj.org/article/69f677a554184995a75623a191483dc2
Autor:
Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, Shigeo Shimose, Goki Suda, Changhoon Yoo, Caterina Soldà, Fabio Piscaglia, Giulia Tosetti, Fabio Marra, Caterina Vivaldi, Fabio Conti, Marta Schirripa, Hideki Iwamoto, Takuya Sho, So Heun Lee, Mario Domenico Rizzato, Matteo Tonnini, Margherita Rimini, Claudia Campani, Gianluca Masi, Francesco Foschi, Mariangela Bruccoleri, Takumi Kawaguchi, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Andrea Casadei-Gardini, Pietro Lampertico
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and compli
Externí odkaz:
https://doaj.org/article/93da06996cb6459c9ed74984e1ecb6e5
Autor:
Antonella Galiano, Stefania Schiavon, Mariateresa Nardi, Irene Guglieri, Ardi Pambuku, Rosalba Martino, Maital Bolshinsky, Sabina Murgioni, Rossana Intini, Caterina Soldà, Dario Marino, Francesca Daniel, Chiara De Toni, Chiara Pittarello, Benedetta Chiusole, Alessandra Anna Prete, Davide Bimbatti, Floriana Nappo, Mario Caccese, Francesca Bergamo, Antonella Brunello, Sara Lonardi, Vittorina Zagonel
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundEarly activation of palliative care for patients with advanced cancer is central in the treatment trajectory. At the Veneto Institute of Oncology, a simultaneous-care outpatient clinic (SCOC) has been active since 2014, where patients are e
Externí odkaz:
https://doaj.org/article/1f0ca2d93e7d4431883b0b66bbe200d0
Autor:
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Lorenza Rimassa, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Targeted Oncology. 18:221-233
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39b2961bc5a8d3120e8844ce31ae7f1b
https://doi.org/10.1007/s11523-023-00953-x
https://doi.org/10.1007/s11523-023-00953-x
Autor:
Gruppo, Ottavia De Simoni, Luca Dal Santo, Marco Scarpa, Giada Munari, Ylenia Camilla Spolverato, Antonio Scapinello, Sara Lonardi, Caterina Soldà, Francesca Bergamo, Alberto Fantin, Romeo Bardini, Pierluigi Pilati, Matteo Fassan, Mario
Publikováno v:
Current Oncology; Volume 30; Issue 6; Pages: 5515-5528
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly immunosuppressive tumor microenvironment (TME). The aim of this study is to determine the potential significant TME immune markers of long-term survival. Methods: We ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::c00fe622853cb52ae7d89a6ef514096c
Autor:
Valentina Burgio, Massimo Iavarone, Giovan Giuseppe Di Costanzo, Fabio Marra, Sara Lonardi, Emiliano Tamburini, Fabio Piscaglia, Gianluca Masi, Ciro Celsa, Francesco Giuseppe Foschi, Marianna Silletta, Daniela Caterina Amoruso, Margherita Rimini, Mariangela Bruccoleri, Raffaella Tortora, Claudia Campani, Caterina Soldà, Massimo Giuseppe Viola, Antonella Forgione, Fabio Conti, Francesca Salani, Silvia Catanese, Carmelo Marco Giacchetto, Claudia Angela Maria Fulgenzi, Carmine Coppola, Pietro Lampertico, Antonio Pellino, Gabriele Rancatore, Giuseppe Cabibbo, Francesca Ratti, Federica Pedica, Angelo Della Corte, Massimo Colombo, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Cancer Management and Research, Vol Volume 13, Pp 9379-9389 (2021)
Cancer Management and Research
Cancer Management and Research
Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::869036421242f17f999f6b357dba8cdd
https://www.dovepress.com/real-life-clinical-data-of-lenvatinib-versus-sorafenib-for-unresectabl-peer-reviewed-fulltext-article-CMAR
https://www.dovepress.com/real-life-clinical-data-of-lenvatinib-versus-sorafenib-for-unresectabl-peer-reviewed-fulltext-article-CMAR
Autor:
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Purpose: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. Methods: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c44a7f9afd3ac1d109f57a5526a43ce
https://hdl.handle.net/10447/583022
https://hdl.handle.net/10447/583022
